Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FT 576

Next Previous
Drug Profile

FT 576

Alternative Names: CAR-BCMA+hnCD16+IL-15RF+CD38KO engineered iPSC-derived NK cell therapy; FT-576

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fate Therapeutics; University of Minnesota
  • Developer Fate Therapeutics
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies; Natural killer cell therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple myeloma

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in USA (Parenteral)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Monotherapy, Second-line therapy or greater) in USA (Parenteral)
  • 13 Dec 2022 Pharmacodynamics data from preclinical studies in multiple myeloma was released by Fate Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top